Skip to main content
NCBI home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 2005 Sep;59(9):740–748. doi: 10.1136/jech.2005.033316

Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives

N Krieger 1, I Lowy 1, R Aronowitz 1, J Bigby 1, K Dickersin 1, E Garner 1, J Gaudilliere 1, C Hinestrosa 1, R Hubbard 1, P Johnson 1, S Missmer 1, J Norsigian 1, C Pearson 1, C Rosenberg 1, L Rosenberg 1, B Rosenkrantz 1, B Seaman 1, C Sonnenschein 1, A Soto 1, J Thornton 1, G Weisz 1
PMCID: PMC1733142  PMID: 16100311

Abstract

Routine acceptance of use of hormone replacement therapy (HRT) was shattered in 2002 when results of the largest HRT randomised clinical trial, the women's health initiative, indicated that long term use of oestrogen plus progestin HRT not only was associated with increased risk of cancer but, contrary to expectations, did not decrease, and may have increased, risk of cardiovascular disease. In June 2004 a group of historians, epidemiologists, biologists, clinicians, and women's health advocates met to discuss the scientific and social context of and response to these findings. It was found that understanding the evolving and contending knowledge on hormones and health requires: (1) considering its societal context, including the impact of the pharmaceutical industry, the biomedical emphasis on individualised risk and preventive medicine, and the gendering of hormones; and (2) asking why, for four decades, since the mid-1960s, were millions of women prescribed powerful pharmacological agents already demonstrated, three decades earlier, to be carcinogenic? Answering this question requires engaging with core issues of accountability, complexity, fear of mortality, and the conduct of socially responsible science.

Full Text

The Full Text of this article is available as a PDF (111.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barkhem Tomas, Nilsson Stefan, Gustafsson Jan-Ake. Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am J Pharmacogenomics. 2004;4(1):19–28. doi: 10.2165/00129785-200404010-00003. [DOI] [PubMed] [Google Scholar]
  2. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991 Sep 15;115(6):455–456. doi: 10.7326/0003-4819-115-6-455. [DOI] [PubMed] [Google Scholar]
  3. Barrett-Connor E., Stuenkel C. A. Hormone replacement therapy (HRT)--risks and benefits. Int J Epidemiol. 2001 Jun;30(3):423–426. doi: 10.1093/ije/30.3.423. [DOI] [PubMed] [Google Scholar]
  4. Barrett-Connor Elizabeth. Commentary: observation versus intervention--what's different? Int J Epidemiol. 2004 May 27;33(3):457–459. doi: 10.1093/ije/dyh123. [DOI] [PubMed] [Google Scholar]
  5. Bell S. E. Changing ideas: the medicalization of menopause. Soc Sci Med. 1987;24(6):535–542. doi: 10.1016/0277-9536(87)90343-1. [DOI] [PubMed] [Google Scholar]
  6. Buist Diana S. M., Newton Katherine M., Miglioretti Diana L., Beverly Kevin, Connelly Maureen T., Andrade Susan, Hartsfield Cynthia L., Wei Feifei, Chan K. Arnold, Kessler Larry. Hormone therapy prescribing patterns in the United States. Obstet Gynecol. 2004 Nov;104(5 Pt 1):1042–1050. doi: 10.1097/01.AOG.0000143826.38439.af. [DOI] [PubMed] [Google Scholar]
  7. DeVito M. J., Birnbaum L. S., Farland W. H., Gasiewicz T. A. Comparisons of estimated human body burdens of dioxinlike chemicals and TCDD body burdens in experimentally exposed animals. Environ Health Perspect. 1995 Sep;103(9):820–831. doi: 10.1289/ehp.95103820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Egeland G. M., Sweeney M. H., Fingerhut M. A., Wille K. K., Schnorr T. M., Halperin W. E. Total serum testosterone and gonadotropins in workers exposed to dioxin. Am J Epidemiol. 1994 Feb 1;139(3):272–281. doi: 10.1093/oxfordjournals.aje.a116994. [DOI] [PubMed] [Google Scholar]
  9. Ekbom A., Trichopoulos D., Adami H. O., Hsieh C. C., Lan S. J. Evidence of prenatal influences on breast cancer risk. Lancet. 1992 Oct 24;340(8826):1015–1018. doi: 10.1016/0140-6736(92)93019-j. [DOI] [PubMed] [Google Scholar]
  10. Ettinger B. Overview of estrogen replacement therapy: a historical perspective. Proc Soc Exp Biol Med. 1998 Jan;217(1):2–5. doi: 10.3181/00379727-217-44198. [DOI] [PubMed] [Google Scholar]
  11. Ettinger Bruce, Grady Deborah, Tosteson Anna N. A., Pressman Alice, Macer Judith L. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol. 2003 Dec;102(6):1225–1232. doi: 10.1016/j.obstetgynecol.2003.08.007. [DOI] [PubMed] [Google Scholar]
  12. Fee E., Krieger N. Understanding AIDS: historical interpretations and the limits of biomedical individualism. Am J Public Health. 1993 Oct;83(10):1477–1486. doi: 10.2105/ajph.83.10.1477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grady D., Rubin S. M., Petitti D. B., Fox C. S., Black D., Ettinger B., Ernster V. L., Cummings S. R. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992 Dec 15;117(12):1016–1037. doi: 10.7326/0003-4819-117-12-1016. [DOI] [PubMed] [Google Scholar]
  14. Gray L. E., Ostby J. S., Kelce W. R. A dose-response analysis of the reproductive effects of a single gestational dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin in male Long Evans Hooded rat offspring. Toxicol Appl Pharmacol. 1997 Sep;146(1):11–20. doi: 10.1006/taap.1997.8223. [DOI] [PubMed] [Google Scholar]
  15. Grodstein Francine, Clarkson Thomas B., Manson JoAnn E. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med. 2003 Feb 13;348(7):645–650. doi: 10.1056/NEJMsb022365. [DOI] [PubMed] [Google Scholar]
  16. Haag Eric S. Meeting review: the microevolution of development. Evol Dev. 2003 Jan-Feb;5(1):1–2. doi: 10.1046/j.1525-142x.2003.03001.x. [DOI] [PubMed] [Google Scholar]
  17. Haenszel W., Curnen M. G. The first fifty years of the Connecticut Tumor Registry: reminiscences and prospects. Yale J Biol Med. 1986 Sep-Oct;59(5):475–484. [PMC free article] [PubMed] [Google Scholar]
  18. Hemminki E., Sihvo S. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol. 1993 Dec;82(6):1021–1028. [PubMed] [Google Scholar]
  19. Henderson I. C. Risk factors for breast cancer development. Cancer. 1993 Mar 15;71(6 Suppl):2127–2140. doi: 10.1002/1097-0142(19930315)71:6+<2127::aid-cncr2820711602>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  20. Hersh Adam L., Stefanick Marcia L., Stafford Randall S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004 Jan 7;291(1):47–53. doi: 10.1001/jama.291.1.47. [DOI] [PubMed] [Google Scholar]
  21. Hoover R., Gray L. A., Sr, Cole P., MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med. 1976 Aug 19;295(8):401–405. doi: 10.1056/NEJM197608192950801. [DOI] [PubMed] [Google Scholar]
  22. Houck Judith A. "What do these women want?": Feminist responses to Feminine Forever, 1963-1980. Bull Hist Med. 2003 Spring;77(1):103–132. doi: 10.1353/bhm.2003.0023. [DOI] [PubMed] [Google Scholar]
  23. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 Aug 19;280(7):605–613. doi: 10.1001/jama.280.7.605. [DOI] [PubMed] [Google Scholar]
  24. Hunt Patricia A., Koehler Kara E., Susiarjo Martha, Hodges Craig A., Ilagan Arlene, Voigt Robert C., Thomas Sally, Thomas Brian F., Hassold Terry J. Bisphenol a exposure causes meiotic aneuploidy in the female mouse. Curr Biol. 2003 Apr 1;13(7):546–553. doi: 10.1016/s0960-9822(03)00189-1. [DOI] [PubMed] [Google Scholar]
  25. Kaufert P. A., Lock M. Medicalization of women's third age. J Psychosom Obstet Gynaecol. 1997 Jun;18(2):81–86. doi: 10.3109/01674829709085573. [DOI] [PubMed] [Google Scholar]
  26. Kelsey J. L., Bernstein L. Epidemiology and prevention of breast cancer. Annu Rev Public Health. 1996;17:47–67. doi: 10.1146/annurev.pu.17.050196.000403. [DOI] [PubMed] [Google Scholar]
  27. Kennedy D. L., Baum C., Forbes M. B. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol. 1985 Mar;65(3):441–446. [PubMed] [Google Scholar]
  28. Kennedy D. L., Baum C., Forbes M. B. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol. 1985 Mar;65(3):441–446. [PubMed] [Google Scholar]
  29. Khaw K. T. Healthy aging. BMJ. 1997 Oct 25;315(7115):1090–1096. doi: 10.1136/bmj.315.7115.1090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Koopman-Esseboom C., Morse D. C., Weisglas-Kuperus N., Lutkeschipholt I. J., Van der Paauw C. G., Tuinstra L. G., Brouwer A., Sauer P. J. Effects of dioxins and polychlorinated biphenyls on thyroid hormone status of pregnant women and their infants. Pediatr Res. 1994 Oct;36(4):468–473. doi: 10.1203/00006450-199410000-00009. [DOI] [PubMed] [Google Scholar]
  31. Kopera H. The dawn of hormone replacement therapy. Maturitas. 1991 Sep;13(3):187–188. doi: 10.1016/0378-5122(91)90192-s. [DOI] [PubMed] [Google Scholar]
  32. Kriebel D., Tickner J. Reenergizing public health through precaution. Am J Public Health. 2001 Sep;91(9):1351–1355. doi: 10.2105/ajph.91.9.1351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Krieger N., Northridge M., Gruskin S., Quinn M., Kriebel D., Davey Smith G., Bassett M., Rehkopf D. H., Miller C., HIA "promise and pitfalls" conference group Assessing health impact assessment: multidisciplinary and international perspectives. J Epidemiol Community Health. 2003 Sep;57(9):659–662. doi: 10.1136/jech.57.9.659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Krieger N. Theories for social epidemiology in the 21st century: an ecosocial perspective. Int J Epidemiol. 2001 Aug;30(4):668–677. doi: 10.1093/ije/30.4.668. [DOI] [PubMed] [Google Scholar]
  35. Krieger Nancy. Postmenopausal hormone therapy. N Engl J Med. 2003 Jun 5;348(23):2363–2364. doi: 10.1056/NEJMc030612. [DOI] [PubMed] [Google Scholar]
  36. Kuller Lewis H. Commentary: hazards of studying women: the oestrogen oestrogen/progesterone dilemma. Int J Epidemiol. 2004 May 27;33(3):459–460. doi: 10.1093/ije/dyh122. [DOI] [PubMed] [Google Scholar]
  37. Kurebayashi Hideo, Betsui Hiroshi, Ohno Yasuo. Disposition of a low dose of 14C-bisphenol A in male rats and its main biliary excretion as BPA glucuronide. Toxicol Sci. 2003 Apr 15;73(1):17–25. doi: 10.1093/toxsci/kfg040. [DOI] [PubMed] [Google Scholar]
  38. La Croix A. Z., Newton K. M., Leveille S. G., Wallace J. Healthy aging. A women's issue. West J Med. 1997 Oct;167(4):220–232. [PMC free article] [PubMed] [Google Scholar]
  39. Larson Eric B., Fihn Stephan D., Kirk Lynne M., Levinson Wendy, Loge Ronald V., Reynolds Eileen, Sandy Lewis, Schroeder Steven, Wenger Neil, Williams Mark. The future of general internal medicine. Report and recommendations from the Society of General Internal Medicine (SGIM) Task Force on the Domain of General Internal Medicine. J Gen Intern Med. 2004 Jan;19(1):69–77. doi: 10.1111/j.1525-1497.2004.31337.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Lawlor Debbie A., Davey Smith George, Ebrahim Shah. Commentary: the hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol. 2004 May 27;33(3):464–467. doi: 10.1093/ije/dyh124. [DOI] [PubMed] [Google Scholar]
  41. Lawlor Debbie A., Ebrahim Shah, Davey Smith George. Role of endogenous oestrogen in aetiology of coronary heart disease: analysis of age related trends in coronary heart disease and breast cancer in England and Wales and Japan. BMJ. 2002 Aug 10;325(7359):311–312. doi: 10.1136/bmj.325.7359.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lawlor Debbie A., Smith George Davey, Ebrahim Shah. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health. 2004 Dec;94(12):2149–2154. doi: 10.2105/ajph.94.12.2149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Löwy Ilana, Weisz George. French hormones: progestins and therapeutic variation in France. Soc Sci Med. 2004 Dec 19;60(11):2609–2622. doi: 10.1016/j.socscimed.2004.10.021. [DOI] [PubMed] [Google Scholar]
  44. Ma Jun, Stafford Randall S., Cockburn Iain M., Finkelstein Stan N. A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998. Clin Ther. 2003 May;25(5):1503–1517. doi: 10.1016/s0149-2918(03)80136-4. [DOI] [PubMed] [Google Scholar]
  45. Majumdar Sumit R., Almasi Elizabeth A., Stafford Randall S. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. JAMA. 2004 Oct 27;292(16):1983–1988. doi: 10.1001/jama.292.16.1983. [DOI] [PubMed] [Google Scholar]
  46. Mann C. Women's health research blossoms. Science. 1995 Aug 11;269(5225):766–770. doi: 10.1126/science.7638586. [DOI] [PubMed] [Google Scholar]
  47. Markey Caroline M., Rubin Beverly S., Soto Ana M., Sonnenschein Carlos. Endocrine disruptors: from Wingspread to environmental developmental biology. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):235–244. doi: 10.1016/s0960-0760(02)00272-8. [DOI] [PubMed] [Google Scholar]
  48. McLachlan J. A. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr Rev. 2001 Jun;22(3):319–341. doi: 10.1210/edrv.22.3.0432. [DOI] [PubMed] [Google Scholar]
  49. McPherson Klim, Hemminki Elina. Synthesising licensing data to assess drug safety. BMJ. 2004 Feb 28;328(7438):518–520. doi: 10.1136/bmj.328.7438.518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Mendelsohn M. E., Karas R. H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 Jun 10;340(23):1801–1811. doi: 10.1056/NEJM199906103402306. [DOI] [PubMed] [Google Scholar]
  51. Nawaz H., Katz D. L. American College of Preventive Medicine Practice Policy Statement: perimenopausal and postmenopausal hormone replacement therapy. Am J Prev Med. 1999 Oct;17(3):250–254. doi: 10.1016/s0749-3797(99)00072-0. [DOI] [PubMed] [Google Scholar]
  52. Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1832–1841. doi: 10.1016/s0002-9378(89)80003-1. [DOI] [PubMed] [Google Scholar]
  53. Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1832–1841. doi: 10.1016/s0002-9378(89)80003-1. [DOI] [PubMed] [Google Scholar]
  54. Oberg Mattias, Sjödin Andreas, Casabona Helena, Nordgren Ingrid, Klasson-Wehler Eva, Håkansson Helen. Tissue distribution and half-lives of individual polychlorinated biphenyls and serum levels of 4-hydroxy-2,3,3',4',5-pentachlorobiphenyl in the rat. Toxicol Sci. 2002 Dec;70(2):171–182. doi: 10.1093/toxsci/70.2.171. [DOI] [PubMed] [Google Scholar]
  55. Oxford A. E. Observations Concerning the Growth and Metabolic Activities of Myxococci in a Simple Protein-free Liquid Medium. J Bacteriol. 1947 Feb;53(2):129–138. doi: 10.1128/jb.53.2.129-138.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Palmlund I. The marketing of estrogens for menopausal and postmenopausal women. J Psychosom Obstet Gynaecol. 1997 Jun;18(2):158–164. doi: 10.3109/01674829709085582. [DOI] [PubMed] [Google Scholar]
  57. Palmlund I. The social construction of menopause as risk. J Psychosom Obstet Gynaecol. 1997 Jun;18(2):87–94. doi: 10.3109/01674829709085574. [DOI] [PubMed] [Google Scholar]
  58. Patandin S., Lanting C. I., Mulder P. G., Boersma E. R., Sauer P. J., Weisglas-Kuperus N. Effects of environmental exposure to polychlorinated biphenyls and dioxins on cognitive abilities in Dutch children at 42 months of age. J Pediatr. 1999 Jan;134(1):33–41. doi: 10.1016/s0022-3476(99)70369-0. [DOI] [PubMed] [Google Scholar]
  59. Petitti D. B. Coronary heart disease and estrogen replacement therapy. Can compliance bias explain the results of observational studies? Ann Epidemiol. 1994 Mar;4(2):115–118. doi: 10.1016/1047-2797(94)90056-6. [DOI] [PubMed] [Google Scholar]
  60. Petitti Diana B. Hormone replacement therapy for prevention: more evidence, more pessimism. JAMA. 2002 Jul 3;288(1):99–101. doi: 10.1001/jama.288.1.99. [DOI] [PubMed] [Google Scholar]
  61. Petitti Diana. Commentary: hormone replacement therapy and coronary heart disease: four lessons. Int J Epidemiol. 2004 May 27;33(3):461–463. doi: 10.1093/ije/dyh192. [DOI] [PubMed] [Google Scholar]
  62. Posthuma W. F., Westendorp R. G., Vandenbroucke J. P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994 May 14;308(6939):1268–1269. doi: 10.1136/bmj.308.6939.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Postmenopausal estrogen use and heart disease. N Engl J Med. 1986 Jul 10;315(2):131–136. doi: 10.1056/NEJM198607103150213. [DOI] [PubMed] [Google Scholar]
  64. Rhoades F. P. Minimizing the menopause. J Am Geriatr Soc. 1967 Apr;15(4):346–354. doi: 10.1111/j.1532-5415.1967.tb02806.x. [DOI] [PubMed] [Google Scholar]
  65. Rosenberg L. Hormone replacement therapy: the need for reconsideration. Am J Public Health. 1993 Dec;83(12):1670–1673. doi: 10.2105/ajph.83.12.1670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Ross R. K., Paganini-Hill A., Gerkins V. R., Mack T. M., Pfeffer R., Arthur M., Henderson B. E. A case-control study of menopausal estrogen therapy and breast cancer. JAMA. 1980 Apr 25;243(16):1635–1639. [PubMed] [Google Scholar]
  67. Russo J., Hu Y. F., Yang X., Russo I. H. Developmental, cellular, and molecular basis of human breast cancer. J Natl Cancer Inst Monogr. 2000;(27):17–37. doi: 10.1093/oxfordjournals.jncimonographs.a024241. [DOI] [PubMed] [Google Scholar]
  68. Sackett David L. The arrogance of preventive medicine. CMAJ. 2002 Aug 20;167(4):363–364. [PMC free article] [PubMed] [Google Scholar]
  69. Smith D. C., Prentice R., Thompson D. J., Herrmann W. L. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975 Dec 4;293(23):1164–1167. doi: 10.1056/NEJM197512042932302. [DOI] [PubMed] [Google Scholar]
  70. Soto A. M., Sonnenschein C. The two faces of janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 2001 Nov 21;93(22):1673–1675. doi: 10.1093/jnci/93.22.1673. [DOI] [PubMed] [Google Scholar]
  71. Stampfer M. J., Colditz G. A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 Jan;20(1):47–63. doi: 10.1016/0091-7435(91)90006-p. [DOI] [PubMed] [Google Scholar]
  72. Stampfer Meir. Commentary: hormones and heart disease: do trials and observational studies address different questions? Int J Epidemiol. 2004 May 27;33(3):454–455. doi: 10.1093/ije/dyh191. [DOI] [PubMed] [Google Scholar]
  73. Sturgeon S. R., Schairer C., Brinton L. A., Pearson T., Hoover R. N. Evidence of a healthy estrogen user survivor effect. Epidemiology. 1995 May;6(3):227–231. doi: 10.1097/00001648-199505000-00006. [DOI] [PubMed] [Google Scholar]
  74. Thornton Joseph W., McCally Michael, Houlihan Jane. Biomonitoring of industrial pollutants: health and policy implications of the chemical body burden. Public Health Rep. 2002 Jul-Aug;117(4):315–323. doi: 10.1016/S0033-3549(04)50167-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Tunstall-Pedoe H. Myth and paradox of coronary risk and the menopause. Lancet. 1998 May 9;351(9113):1425–1427. doi: 10.1016/S0140-6736(97)11321-6. [DOI] [PubMed] [Google Scholar]
  76. Ulrich E. M., Caperell-Grant A., Jung S. H., Hites R. A., Bigsby R. M. Environmentally relevant xenoestrogen tissue concentrations correlated to biological responses in mice. Environ Health Perspect. 2000 Oct;108(10):973–977. doi: 10.1289/ehp.00108973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Vandenbroucke J. P. Postmenopausal oestrogen and cardioprotection. Lancet. 1991 Jun 15;337(8755):1482–1483. doi: 10.1016/0140-6736(91)93173-7. [DOI] [PubMed] [Google Scholar]
  78. Vandenbroucke Jan P. Commentary: the HRT story: vindication of old epidemiological theory. Int J Epidemiol. 2004 May 27;33(3):456–457. doi: 10.1093/ije/dyh121. [DOI] [PubMed] [Google Scholar]
  79. WILSON R. A., WILSON T. A. The fate of the nontreated postmenopausal woman: a plea for the maintenance of adequate estrogen from puberty to the grave. J Am Geriatr Soc. 1963 Apr;11:347–362. doi: 10.1111/j.1532-5415.1963.tb00068.x. [DOI] [PubMed] [Google Scholar]
  80. Watkins Elizabeth Siegel. "Doctor, are you trying to kill me?": ambivalence about the patient package insert for estrogen. Bull Hist Med. 2002 Spring;76(1):84–104. doi: 10.1353/bhm.2002.0050. [DOI] [PubMed] [Google Scholar]
  81. Weinstein M. C. Estrogen use in postmenopausal women--costs, risks, and benefits. N Engl J Med. 1980 Aug 7;303(6):308–316. doi: 10.1056/NEJM198008073030604. [DOI] [PubMed] [Google Scholar]
  82. Wysowski D. K., Golden L., Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995 Jan;85(1):6–10. doi: 10.1016/0029-7844(94)00339-f. [DOI] [PubMed] [Google Scholar]
  83. Yu M. L., Guo Y. L., Hsu C. C., Rogan W. J. Menstruation and reproduction in women with polychlorinated biphenyl (PCB) poisoning: long-term follow-up interviews of the women from the Taiwan Yucheng cohort. Int J Epidemiol. 2000 Aug;29(4):672–677. doi: 10.1093/ije/29.4.672. [DOI] [PubMed] [Google Scholar]
  84. Ziel H. K., Finkle W. D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975 Dec 4;293(23):1167–1170. doi: 10.1056/NEJM197512042932303. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES